
This article was downloaded by: [Memorial University of Newfoundland] On: 18 July 2014, At: 10:12 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/gpss20</u>

Synthesis and Biological Activities of New Chiral Imidazolinone Derivatives

Xiaobo Huang ^{a b} , Dengze Wu ^b , Jinchang Ding ^c , Xichang Zhang ^b , Miaochang Liu ^b , Huayue Wu ^b & Weike Su ^a

^a Key Laboratory of Pharmaceutical Engineering of Ministry of Education, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P. R. China

^b College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou, P. R. China

 $^{\rm c}$ Wenzhou Vocational & Technical College , Wenzhou, P. R. China Published online: 28 Dec 2009.

To cite this article: Xiaobo Huang , Dengze Wu , Jinchang Ding , Xichang Zhang , Miaochang Liu , Huayue Wu & Weike Su (2009) Synthesis and Biological Activities of New Chiral Imidazolinone Derivatives, Phosphorus, Sulfur, and Silicon and the Related Elements, 185:1, 117-128

To link to this article: http://dx.doi.org/10.1080/10426500902717325

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>



Phosphorus, Sulfur, and Silicon, 185:117–128, 2010 Copyright © Taylor & Francis Group, LLC ISSN: 1042-6507 print / 1563-5325 online DOI: 10.1080/10426500902717325

SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW CHIRAL IMIDAZOLINONE DERIVATIVES

Xiaobo Huang,^{1,2} Dengze Wu,² Jinchang Ding,³ Xichang Zhang,² Miaochang Liu,² Huayue Wu,² and Weike Su¹

 ¹Key Laboratory of Pharmaceutical Engineering of Ministry of Education, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P. R. China
²College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou, P. R. China
³Wenzhou Vocational & Technical College, Wenzhou, P. R. China

New optically active 2-thio-4-imidazolinones 3 with a chiral carbon at position-3 were synthesized from isothiocyanates 2, which were obtained from aza-Wittig reactions of vinyliminophosphoranes 1 with CS₂, with easily accessible chiral (S)- or (R)-amino acid methyl ester hydrochlorides. 2-Methylthio-4H-imidazolin-4-ones 4 were obtained by the S-alkylation of compounds 3 in the presence of K_2CO_3 causing partial racemization of the enantiomeric pure products. These compounds were identified by MS, IR, ¹H NMR, ¹³C NMR spectroscopy, and elemental analysis. The structures of enantiomers 3c and 3d were also confirmed by X-ray diffraction analysis. The results of preliminary bioassay indicated that compounds 4 exhibited growth inhibition of barnyard grass and cole root and stalk, and fungicidal activities against Fusarium oxysporium, Rhizoctonia solani, Gibberella zeae, Dothiorella gregaria, and Colletotrichum gossypii.

Supplemental materials are available for this article. Go to the publisher's online edition of Phosphorus, Sulfur, and Silicon and the Related Elements to view the free supplemental file.

Keywords Aza-Wittig reaction; chiral agrochemicals; crystal structure; fungicidal activities; herbicidal activities; imidazolinone derivatives

INTRODUCTION

Imidazolinone derivatives have received increased attention over the past two decades due to their interesting biological activities. Some of them exhibit a broad spectrum of pharmacological activities, such as anticonvulsive,¹ antiviral,² antitumor,³ antibacterial,⁴ and anti-inflammatory.⁵ Most importantly, some imidazolinone derivatives have been

Address correspondence to Weike Su, Key Laboratory of Pharmaceutical Engineering of Ministry of Education, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P.R. China. E-mail: suweike@zjut.edu.cn

Received 31 October 2008; accepted 24 December 2008.

The authors are thankful for the financial support from National Key Technology R&D Program (Grant No. 2007BAI34B00), the National Natural Science Foundation of China (Grant No. 20876147), and the Opening Foundation of Zhejiang Provincial Top-Key Pharmaceutical Discipline (Grant No. 20050603, 20050610, and 20080602).


X. HUANG ET AL.

successfully used in crop protection. Imidazolinone herbicides, for example imazapyr, imazapic, imazethapyr, imazamox, imazamethabenz, and imazaquin are distinguished selective herbicides that act by inhibiting the enzyme acetohydroxyacid synthase (AHAS), also known as acetolactate synthase (ALS), which is a critical enzyme for the biosynthesis of branched-chain amino acids in plants.⁶ Some imidazolinones also have been found to possess fungicidal activities, for example 5-methyl-2-methylthio-5-phenyl-3-phenylamine-3,5dihydro-imidazolin-4-one (RPA407213) shows high fungicidal activities.⁷ What deserves special mention is that the imidazolinone derivatives exhibited above as agrochemicals are chiral compounds. For instance, the imidazolinone ring of imidazolinone herbicide has a chiral carbon to which the methyl and isopropyl groups are attached. It has been reported that the *R*-enantiomer of imazethapyr and other pyridine imidazolinones are 10-fold more inhibitory to AHAS than the S-enantiomer.⁸ Many compounds used in the pharmaceutical and agrochemical industries contain chiral centers, but they are often produced and used as racemic mixtures. Although chiral compounds have potential advantages in terms of regulatory, intellectual property, and marketing benefits, limited access to chiral raw materials and economic synthesis routes are key reasons why single isomers are less common than they might be.⁹ Therefore, the development of more chiral routes is still an attractive topic of study on agrochemicals.

In recent years, the aza-Wittig reaction of iminophosphoranes has attracted considerable attention due to its high potential for the synthesis of nitrogen-containing heterocycles. This method provides one of the best procedures for the formation of carbon–nitrogen double bonds under mild and neutral reaction conditions.¹⁰ Some imidazolinone derivatives, such as 2-alkylthio-4*H*-imidazolin-4-ones, have been synthesized by this method to evaluate their biological activities, and some of them exhibit herbicidal and fungicidal activities.¹¹ Based on the above idea, we now report the synthesis and biological activities of a series of new optically active imidazolinone derivatives with a chiral carbon at position-3.

RESULTS AND DISCUSSION

The synthetic pathway for 2-methylthio-4*H*-imidazolin-4-ones **4** is shown in Scheme 1. The intermediate vinyliminophosphorane **1** synthesized by the method in the literature¹² reacted with CS_2 to give isothiocyanates **2** via an aza-Wittig reaction.




Scheme 1

Compound	\mathbb{R}^1	\mathbb{R}^2	R ³	Yield (%)
3a	Ph	CH ₃	COOCH ₃	58
3b	Ph	COOCH ₃	CH ₃	57
3c	4-Cl-Ph	CH ₃	COOCH ₃	56
3d	4-Cl-Ph	COOCH ₃	CH ₃	55
3e	4-CH ₃ -Ph	CH ₃	COOCH ₃	50
3f	4-CH ₃ -Ph	COOCH ₃	CH ₃	61
3g	4-CH ₃ O-Ph	CH ₃	COOCH ₃	84
3h	4-CH ₃ O-Ph	COOCH ₃	CH ₃	81
3i	Ph	CH ₂ OH	COOCH ₃	64
3ј	4-CH ₃ O-Ph	CH ₂ OH	COOCH ₃	67
3k	4-CH ₃ O-Ph	1H-indol-3-yl	CH ₃	76
31	4-CH ₃ O-Ph	CH ₂ COOCH ₃	COOCH ₃	78
3m	4-CH ₃ O-Ph	CH ₂ CH ₂ COOCH ₃	COOCH ₃	71

Table I Synthesis of compounds 3a-m

Compounds **2** reacted with easily accessible (*S*)- or (*R*)-amino acid methyl ester hydrochlorides in the presence of Et_3N to give new single chiral 2-thio-4-imidazolinones **3** by an intramolecular cyclocondensation at room temperature in 50–84% yields (Table I). As can be seen in Scheme 2, the reaction between isothiocyanates **2** and amino acid methyl esters should afford intermediates **5**. According to the previous reports,^{11,13} from these intermediates **5**, the formation of two regioisomeric 2-thio-4-imidazolinones **3** and/or **6** could, in principle, take place. Pure compounds **3** were obtained separately from



Scheme 2

the reaction mixture on a silica gel column, but isomers **6** could not be isolated. Perhaps the main cause is that compounds **3** are more stable in structure in comparison with compounds **6**. Single crystal structures of the enantiomers **3c** and **3d** grown from CH₂Cl₂ and ether (1:1, v/v) were confirmed by X-ray diffraction analysis as shown in Figures 1 and 2. Diffraction measurements were carried out on a Bruker APEX area-detector diffractometer (graphite-monochromatized Mo-K α radiation, $\lambda = 0.71073$ Å). The hydrogen atoms were added according to the theoretical models. The structures were refined by full-matrix least-squares method on F² with anisotropic thermal parameters for all non-hydrogen atoms. The programs for structure solution and refinement were SHELXS-97¹⁴ and SHELXL-97,¹⁵ respectively. Crystal data are summarized in Table II. The crystallographic data was deposited at CCDC.¹⁶ The X-ray crystal structures of **3c** and **3d** indicated the compounds exist as *S*-configuration and *R*-configuration, respectively,




Figure 1 The molecular structure of **3c**, with the atom-numbering scheme. Displacement ellipsoids are drawn at the 50% probability level.

and they are enantiomers. The racemate of **3c** and **3d** was synthesized by the reaction of racemic alanine methyl esters hydrochloride and isothiocyanate and applied to determine the enantiomeric excess (ee) values of **3c** and **3d** by comparing their HPLC data. The ee values of both these compounds were 100% determined by HPLC on Chiralcel OD-H column.¹⁷ The results demonstrated that **3c** and **3d** were pure optical compounds. The target compounds 2-methylthio-*4H*-imidazolin-4-ones **4** were obtained from compounds **3** by using K₂CO₃ as base in 67–92% yields (Table III). In view of using K₂CO₃ as the base in the course of the *S*-alkylation reaction, the racemate of **4c** and **4d** was synthesized in order to determine the optical purity of these compounds. The results showed that the ee values of **4c** and **4d** were 82% and 79%, respectively,¹⁸ and indicated that the presence of K₂CO₃.

The biological activities in vitro of all compounds 4a-4m were investigated according to a method reported in the literature.^{11b} The results are summarized in Tables IV and V (available online in the Supplemental Materials for this article). As far as different configuration of compounds 4 was concerned, on the whole, the inhibitory activities on cole and barnyard grass (*Echinochloa crusgalli*) of *S*-enantiomers of the target compounds were better than those of *R*-enantiomers. But in view of biological activities of enantiomers, they did not show distinguished difference, which might be caused by the partial racemization of the target compounds under base conditions.




Figure 2 The molecular structure of 3d, with the atom-numbering scheme. Displacement ellipsoids are drawn at the 50% probability level.

Entry	3c	3d
Formal	C ₁₄ H ₁₃ ClN ₂ O ₃ S	C ₁₄ H ₁₃ ClN ₂ O ₃ S
Temperature	298(2) K	298(2) K
Wavelength	0.71073	0.71073
Crystal system	Orthorhombic	Orthorhombic
Space group	P212121	P212121
a	7.0847(4) Å	6.6117(6) Å
b	6.6079(5) Å	7.0904(7) Å
с	30.902(2) Å	30.948(3) Å
α	90°	90 °
β	90 °	90 °
Y	90 °	90 °
Volume	1446.69(17) Å ³	1450.8(2) Å ³
Z	4	4
Calculated density	1.491 Mg mm^{-3}	1.487 Mg mm^{-3}
Absorption coefficient	0.419 mm^{-1}	0.418 mm^{-1}
F(000)	672	672
Crystal size	$0.48 \times 0.19 \times 0.17 \text{ mm}$	$0.26 \times 0.17 \times 0.09 \text{ mm}$
θ Range for data collection	1.32–25.26 °	2.63–25.01 °
Limiting indices	$\begin{array}{l} -8 \leq h \leq 5, -7 \leq k \leq 7, \\ -37 \leq l \leq 35 \end{array}$	$\begin{array}{l} -7 \leq h \leq 7, -8 \leq k \leq 8, \\ -25 \leq l \leq 36 \end{array}$
Reflections collection/ unique	7723/2609 [R (int) = 0.0201]	7690/2566 [R (int) = 0.0531]
Completeness to $\theta = 25.19^{\circ}$	99.9%	99.9%
Absorption correction	Semi-empirical from equivalents	Semi-empirical from equivalents
Refinement method	Full-matrix least-squares on F ²	Full-matrix least-squares on F ²
Goodness-of fit on F ²	1.156	1.035
Final R indices $[I > 2\sigma (I)]$	$R_1 = 0.0440, wR_2 = 0.1151$	$R_1 = 0.0857, wR_2 = 0.2369$
Largest diff. Peak and hole	$0.310 \text{ and } -0.242 \text{ eA}^{-3}$	$0.542 \text{ and } -0.352 \text{ eA}^{-3}$

Table II Crystal data and summary of data collection and structure refinement of enantiomers 3c and 3d

Table III Synthesis of compounds 4a-m

Compound	\mathbf{R}^1	\mathbb{R}^2	R ³	Yield (%)
4a	Ph	CH ₃	COOCH ₃	79
4b	Ph	COOCH ₃	CH ₃	92
4c	4-Cl-Ph	CH ₃	COOCH ₃	70
4d	4-Cl-Ph	COOCH ₃	CH ₃	83
4e	4-CH ₃ -Ph	CH ₃	COOCH ₃	87
4f	4-CH ₃ -Ph	COOCH ₃	CH ₃	67
4g	4-CH ₃ O-Ph	CH ₃	COOCH ₃	72
4h	4-CH ₃ O-Ph	COOCH ₃	CH ₃	72
4i	Ph	CH ₂ OH	COOCH ₃	67
4j	4-CH ₃ O-Ph	CH ₂ OH	COOCH ₃	68
4k	4-CH ₃ O-Ph	1H-indol-3-yl	CH ₃	80
41	4-CH ₃ O-Ph	CH ₂ COOCH ₃	COOCH ₃	90
4m	4-CH ₃ O-Ph	CH ₂ CH ₂ COOCH ₃	COOCH ₃	83

X. HUANG ET AL.

CONCLUSIONS

In conclusion, we have developed an efficient synthesis of novel chiral 2-thio-4imidazolinones **3** via a tandem aza-Wittig reaction that utilizes easily accessible starting material and allows mild reaction conditions with satisfactory yields. The structures of enantiomers **3c** and **3d** were confirmed by X-ray diffraction analysis. Due to the use of the base in the *S*-alkylation reaction of compounds **3**, racemization of a small proportion of the target 2-methylthio-4*H*-imidazolin-4-ones **4** was detected by HPLC. The results of the bioassay indicated some compounds **4** exhibited not only inhibition of barnyard and cole grass, but also fungicidal activities against *Fusarium oxysporium*, *Rhizoctonia solani*, *Gibberella zeae*, *Dothiorella gregaria*, and *Colletotrichum gossypii*.

EXPERIMENTAL

The ¹H NMR spectra were obtained using an Avance-300 spectrometer 300 MHz for NMR and 75 MHz for ¹³C NMR and reported as parts per million (ppm) from the internal standard TMS. IR spectra were taken on Equinox-55 Infrared spectrometer. The ee value determination was carried out using chiral P-E Series200 HPLC with a Chiralpak OD-H column on a Waters chromatograph with a P-E Series 200 UV/vis detector. Mass spectra were recorded on an Agilent 1100LC/MSD Trap SL spectrometer. Elementary analyses were taken on an Elementar Vario Micro analyzer. Optical rotations were measured with a Rudolph Autopol IV automatic polarimeter. Melting points were determined on X₄ microscopic melting apparatus (uncorrected).

General Preparation of 2-Thio-4-imidazolinones 3

To a solution of vinyliminophosphoranes **1** (5 mmol) in dry dichloromethane, excess CS_2 (50 mmol) was added, and the mixture was refluxed for 29 h under nitrogen. The solvent was removed under pressure and ether, and petroleum ether (20 mL, 1:2, v/v) was added to precipitate triphenylphosphine sulfide, which was removed by filtration. The filtrate was evaporated to give isothiocyanates **2**, which was used without purification. To a solution of the crude **2** in dry CH₃CN (20 mL), (*S*)- or (*R*)-amino acid methyl esters hydrochloride (5 mmol) and Et₃N (5 mmol) were added. The mixture was allowed to reflux for 3 h and then to cool to room temperature. After evaporation, the residue was separated by column chromatography (petroleum ether/ethyl acetate, 10:1, v/v) to afford 2-thio-4-imidazolinones **3**.

(S)-2-(4-Benzylidene-5-oxo-2-thio-imidazolidin-1-yl)propanoic acid methyl ester (3a). Appearance: yellow solid; mp 148–150°C; $[\alpha]_{20}^{D} = -6.9$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.71 (d, 3H, J = 7.3 Hz, CH₃), 3.76 (s, 3H, OCH₃), 5.40 (q, 1H, J = 7.3 Hz, CH), 6.75 (s, 1H, = C–H), 7.49-7.41 (m, 5H, Ar–H), 8.90 (s, 1H, N–H); ¹³C NMR (75 MHz, CDCl₃): δ 14.42, 50.89, 52.81, 114.09, 126.03, 129.19, 129.50, 129.88, 132.64, 162.82, 169.53, 177.29; IR (KBr) ν /cm⁻¹: 1269, 1440, 1642, 1726, 3414; MS: m/z = 291 (M⁺+1); calcd. for C₁₄H₁₄N₂O₃S (%): C, 57.92; H, 4.86; N, 9.65; found (%): C, 57.89; H, 4.82; N, 9.69.

(R)-2-(4-Benzylidene-5-oxo-2-thio-imidazolidin-1-yl)propanoic acid methyl ester (3b). Appearance: yellow solid; mp 147–149°C; $[\alpha]_{20}^{D} = +7.2$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.70 (d, 3H, J = 7.3 Hz, CH₃), 3.75 (s, 3H, OCH₃), 5.40 (q, 1H, J = 7.3 Hz, CH), 6.74 (s, 1H, = C–H), 7.49-7.38 (m, 5H, Ar–H),

9.15 (s, 1H, N–H); ¹³C NMR (75 MHz, CDCl₃): δ 14.44, 50.91, 52.80, 114.12, 126.06, 129.23, 129.55, 129.80, 132.60, 162.78, 169.49, 177.27; IR (KBr) ν /cm⁻¹: 1267, 1443, 1640, 1725, 3410; MS: m/z = 291 (M⁺+1); calcd. for C₁₄H₁₄N₂O₃S (%): C, 57.92; H, 4.86; N, 9.65; found (%): C, 57.88; H, 4.85; N, 9.60.

(S)-2-[4-(4-Chlorobenzylidene)-5-oxo-2-thio-imidazolidin-1-yl]propanoic acid methyl ester (3c). Appearance: yellow solid; mp 170–172°C; $[α]_{20}^{D} = -4.0$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.71 (d, 3H, J = 7.2 Hz, CH₃), 3.77 (s, 3H, OCH₃), 5.40 (q, 1H, J = 7.2 Hz, CH), 6.68 (s, 1H, = C–H), 7.37 (d, 2H, J = 8.6 Hz, Ar–H), 7.45 (d, 2H, J = 8.6 Hz, Ar–H), 8.63 (s, 1H, N–H); ¹³C NMR (75 MHz, CDCl₃): δ 14.41, 51.00, 52.85, 112.40, 126.29, 129.81, 130.37, 131.13, 135.89, 162.71, 169.44, 177.39; IR (KBr) ν/cm^{-1} : 1274, 1447, 1644, 1726, 3348; MS: m/z = 324 (M⁺); calcd. for C₁₄H₁₃ClN₂O₃S (%): C, 51.77; H, 4.03; N, 8.63; found (%): C, 51.66; H, 4.05; N, 8.69.

(R)-2-[4-(4-Chlorobenzylidene)-5-oxo-2-thio-imidazolidin-1-yl]propanoic acid methyl ester (3d). Appearance: yellow solid; mp 168–170°C; $[\alpha]_{20}^{D} = +3.9$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.71 (d, 3H, J = 7.2 Hz, CH₃), 3.77 (s, 3H, OCH₃), 5.40 (q, 1H, J = 7.2 Hz, CH), 6.67 (s, 1H, = C–H), 7.38 (d, 2H, J = 8.6 Hz, Ar–H), 7.45 (d, 2H, J = 8.6 Hz, Ar–H), 8.95 (s, 1H, N–H); ¹³C NMR (75 MHz, CDCl₃): δ 14.36, 50.90, 52.83, 112.57, 126.16, 129.71, 130.41, 130.99, 135.80, 162.70, 169.44, 177.30; IR (KBr) ν /cm⁻¹: 1273, 1440, 1645, 1725, 3340; MS: m/z = 324 (M⁺); calcd. for C₁₄H₁₃ClN₂O₃S (%): C, 51.77; H, 4.03; N, 8.63; found (%): C, 51.70; H, 3.99; N, 8.65.

(S)-2-[4-(4-Methylbenzylidene)-5-oxo-2-thio-imidazolidin-1-yl]propanoic acid methyl ester (3e). Appearance: yellow solid; mp 161–162°C; $[\alpha]_{20}^{D} = -12.0$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.69 (d, 3H, J = 7.2 Hz, CH₃), 2.40 (s, 3H, CH₃), 3.76 (s, 3H, OCH₃), 5.40 (q, 1H, J = 7.2 Hz, CH), 6.73 (s, 1H, = C–H), 7.28 (d, 2H, J = 8.5 Hz, Ar–H), 7.45 (d, 2H, J = 8.5 Hz, Ar–H), 8.98 (s, 1H, N–H); ¹³C NMR (75 MHz, CDCl₃): δ 14.42, 21.51, 50.92, 52.70, 114.14, 125.74, 129.14, 130.29, 131.03, 139.72, 162.70, 169.73, 176.92; IR (KBr) ν /cm⁻¹: 1271, 1449, 1645, 1729, 3438; MS: m/z = 305 (M⁺+1); calcd. for C₁₅H₁₆N₂O₃S (%): C, 59.19; H, 5.30; N, 9.20; found (%): C, 59.23; H, 5.28; N, 9.15.

(R)-2-[4-(4-Methylbenzylidene)-5-oxo-2-thio-imidazolidin-1-yl]propanoic acid methyl ester (3f). Appearance: yellow solid; mp 160–161°C; $[\alpha]_{20}^{D} = +11.9$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.69 (d, 3H, J = 7.2 Hz, CH₃), 2.38 (s, 3H, CH₃), 3.75 (s, 3H, OCH₃), 5.40 (q, 1H, J = 7.3 Hz, CH), 6.71 (s, 1H, = C–H), 7.25 (d, 2H, J = 8.5 Hz, Ar–H), 7.34 (d, 2H, J = 8.5 Hz, Ar–H), 9.11 (s, N–H, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 14.37, 21.48, 50.80, 52.74, 114.41, 125.26, 129.22, 129.74, 130.20, 140.52, 162.81, 169.51, 177.00; IR (KBr) ν /cm⁻¹: 1269, 1447, 1640, 1726, 3430; MS: m/z = 305 (M⁺+1); calcd. for C₁₅H₁₆N₂O₃S (%): C, 59.19; H, 5.30; N, 9.20; found (%): C, 59.16; H, 5.24; N, 9.12.

(S)-2-[4-(4-Methoxybenzylidene)-5-oxo-2-thio-imidazolidin-1-yl]propanoic acid methyl ester (3g). Appearance: yellow solid; mp 175–177°C; $[\alpha]_{20}^{D} = -23.2$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.71 (d, 3H, J = 7.3 Hz, CH₃), 3.76 (s, 3H, OCH₃), 3.87 (s, 3H, Ar=OCH₃), 5.40 (q, 1H, J = 7.3 Hz, CH), 6.72 (s, 1H, = C=H), 6.99 (d, 2H, J = 8.8 Hz, Ar=H), 7.40 (d, 2H, J = 8.8 Hz, Ar=H), 8.73 (s, N=H, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 14.41, 50.87, 52.74, 55.48, 114.34, 115.12, 124.37, 125.21, 131.02, 161.03, 162.87, 169.55, 176.88; IR (KBr) ν /cm⁻¹: 1263, 1463, 1646, 1723, 3437; MS: m/z = 321 (M⁺+1); calcd. for C₁₅H₁₆N₂O₄S (%): C, 56.24; H, 5.03; N, 8.74; found (%): C, 56.14; H, 5.05; N, 8.79.

(R)-2-[4-(4-Methoxybenzylidene)-5-oxo-2-thio-imidazolidin-1-yl]propan oic acid methyl ester (3h). Appearance: yellow solid; mp 174–176°C; $[\alpha]_{20}^{D} = +22.9$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.70 (d, 3H, J = 7.3 Hz, CH₃), 3.75 (s, 3H, OCH₃), 3.86 (s, 3H, Ar–OCH₃), 5.40 (q, 1H, J = 7.3 Hz, CH), 6.71 (s, 1H, CH), 6.99 (d, 2H, J = 8.8 Hz, Ar–H), 7.41 (d, 2H, J = 8.8 Hz, Ar–H), 8.96 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃): δ 14.37, 50.79, 52.74, 55.43, 114.45, 115.03, 124.25, 125.10, 131.05, 160.96, 162.85, 169.54, 176.79; IR (KBr) ν /cm⁻¹: 1262, 1461, 1645, 1720, 3430; MS: m/z = 321 (M⁺+1); calcd. for C₁₅H₁₆N₂O₄S (%): C, 56.24; H, 5.03; N, 8.74; found (%): C, 56.20; H, 5.01; N, 8.76.

(S)-2-(4-Benzylidene-5-oxo-2-thio-imidazolidin-1-yl)-3-hydroxy-propan oic acid methyl ester (3i). Appearance: yellow solid; mp 189–190°C; $[\alpha]_{20}^{D} = +24.0$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 3.81 (s, 3H, OCH₃), 4.27-4.24 (m, 2H, CH₂), 5.51 (t, 1H, J = 5.2 Hz, CH), 6.80 (s, 1H, = C–H), 7.51-7.40 (m, 5H, Ar–H), 8.96 (s, N–H, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 52.91, 57.96, 60.56, 114.76, 125.86, 129.18, 129.57, 130.08, 132.56, 163.80, 167.87, 177.58; IR (KBr) ν /cm⁻¹: 1238, 1473, 1645, 1732, 3437; MS: m/z = 307 (M⁺+1); calcd. for C₁₄H₁₄N₂O₄S (%): C, 54.89; H, 4.61; N, 9.14; found (%): C, 54.95; H, 4.66; N, 9.09.

(S)-3-Hydroxy-2-[4-(4-methoxybenzylidene)-5-oxo-2-thio-imidazolidin-1-yl]propanoic acid methyl ester (3j). Appearance: yellow solid; mp 220–222°C; $[α]_{20}^{D} = +11.9$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 3.82 (s, 3H, OCH₃), 3.89 (s, 3H, Ar–OCH₃), 4.33-4.26 (m, 2H, CH₂), 5.53 (t, 1H, J = 5.0 Hz, CH), 6.78 (s, 1H, = C–H), 7.03 (d, 2H, J = 8.8 Hz, Ar–H), 7.42 (d, 2H, J = 8.8 Hz, Ar–H), 8.90 (s, 1H, N–H); ¹³C NMR (75 MHz, CDCl₃): δ 52.74, 55.51, 58.12, 60.70, 115.22, 125.66, 129.67, 133.45, 135.79, 161.42, 163.27, 167.46, 177.07; IR (KBr) ν/cm⁻¹: 1236, 1470, 1640, 1735, 3437; MS: m/z = 337 (M⁺+1); calcd. for C₁₅H₁₆N₂O₅S (%): C, 53.56; H, 4.79; N, 8.33; found (%): C, 53.66; H, 4.73; N, 9.29.

(S)-3-(1H-Indol-3-yl)-2-[4-(4-methoxybenzylidene)-5-oxo-2-thio-imidazo lidin-1-yl]propanoic acid methyl ester (3k). Appearance: yellow solid, mp 88–89°C; $[\alpha]_{20}^{D} = -215.9$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 3.93-3.72 (m, 8H, CH₂ & COOCH₃ & Ar=OCH₃), 5.71-5.66 (m, 1H, CH), 6.60 (s, 1H, = C=H), 7.99-6.91 (m, 10H, Ar=H & N=H), 8.56 (s, 1H, N=H); ¹³C NMR (75 MHz, CDCl₃): δ 24.18, 52.79, 55.45, 55.76, 111.07, 115.01, 118.66, 119.51, 122.05, 122.99, 124.19, 125.19, 130.96, 136.08, 160.91, 163.21, 169.09, 177.18; IR (KBr) ν /cm⁻¹: 1258, 1463, 1604, 1730, 3414; MS: m/z = 436 (M⁺+1); calcd. for C₂₃H₂₁N₃O₄S (%): C, 63.43; H, 4.86; N, 9.65; found (%): C, 63.30; H, 4.90; N, 9.61.

(S)-2-[4-(4-Methoxybenzylidene)-5-oxo-2-thio-imidazolidin-1-yl]succinic acid dimethyl ester (3l). Appearance: yellow solid; mp 48–50°C; $[\alpha]_{20}^{D} = -79.6$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 3.47-3.12 (m, 2H, CH₂), 3.75 (s, 3H, OCH₃), 3.84 (s, 3H, OCH₃), 3.86 (s, 3H, Ar-OCH₃), 5.83-5.78 (m, 1H, CH), 6.72 (s, 1H, = C-H), 6.91 (d, 2H, J = 8.1 Hz, Ar-H), 7.41 (d, 2H, J = 8.1 Hz, Ar-H), 9.06 (s, 1H, N-H); ¹³C NMR (75 MHz, CDCl₃): δ 33.49, 51.14, 52.15, 53.10, 55.48, 114.03, 115.06, 124.03, 125.07, 131.27, 161.12, 163.17, 168.25, 170.44, 176.61; IR (KBr) ν/cm^{-1} : 1256, 1468, 1602, 1645, 1740, 3417; MS: m/z = 379 (M⁺+1); calcd. for C₁₇H₁₈N₂O₆S (%): C, 53.96; H, 4.79; N, 7.40; found (%): C, 53.85; H, 4.75; N, 7.45.

(S)-2-[4-(4-Methoxybenzylidene)-5-oxo-2-thio-imidazolidin-1-yl]pentan edioic acid dimethyl ester (3m). Appearance: yellow solid; mp 70–72°C; $[\alpha]_{20}^{D}$ = -16.8 (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 2.70-2.17 (m, 4H, 2CH₂), 3.67 (s, 3H, OCH₃), 3.75 (s, 3H, OCH₃), 3.87 (s, 3H, Ar–OCH₃), 5.41-5.36 (m, 1H, CH), 6.71 (s, 1H, = C–H), 6.98 (d, 2H, J = 8.4 Hz, Ar–H), 7.42 (d, 2H, J = 8.4 Hz, Ar–H), 8.98 (s, 1H, N–H); ¹³C NMR (75 MHz, CDCl₃): δ 23.85, 30.55, 51.84, 52.85, 54.33, 55.51, 114.91, 115.02, 124.06, 125.11, 131.35, 161.10, 163.34, 168.80, 172.84, 177.32; IR (KBr) ν/cm^{-1} : 1257, 1440, 1510, 1580, 1740, 3410; MS: m/z = 393 (M⁺+1); calcd. for C₁₈H₂₀N₂O₆S (%): C, 55.09; H, 5.14; N, 7.14; found (%): C, 54.92; H, 5.10; N, 7.19.

General Preparation of 2-Methylthio-4H-imidazolin-4-ones 4

A mixture of 2-thio-4-imidazolinones **3** (0.77 mol) in dry acetonitrile (20 mL), CH₃I (1.54 mmol), and solid K₂CO₃ (1.3 mmol) was stirred for 3 h at room temperature and then filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by column chromatography (petroleum ether/ethyl acetate, 15:1, v/v) to afford 2-methylthio-4*H*-imidazolin-4-ones **4**.

(S)-2-(4-Benzylidene-2-methylthio-5-oxo-4,5-dihydro-imidazol-1-yl)prop anoic acid methyl ester (4a). Appearance: yellow solid; mp 70–71°C; $[\alpha]_{20}^{D} = -10.6$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.69 (d, 3H, J = 7.4 Hz, CH₃), 2.77 (s, 3H, SCH₃), 3.76 (s, 3H, OCH₃), 4.82 (q, 1H, J = 7.4 Hz, CH), 6.97 (s, 1H, = C–H), 7.44-7.36 (m, 3H, Ar–H), 8.15 (d, 2H, J = 8.0 Hz, Ar–H); ¹³C NMR (75 MHz, CDCl₃): δ 13.50, 15.51, 49.96, 52.80, 124.29, 128.63, 129.87, 131.97, 134.39, 137.88, 163.88, 169.27, 169.68; IR (KBr) ν/cm^{-1} : 1269, 1400, 1440, 1640, 1730; MS: m/z = 305 (M⁺+1); calcd. for C₁₅H₁₆N₂O₃S (%): C, 59.19; H, 5.30; N, 9.20; found (%): C, 59.12; H, 5.27; N, 9.27.

(R)-2-(4-Benzylidene-2-methylthio-5-oxo-4,5-dihydro-imidazol-1-yl)prop anoic acid methyl ester (4b). Appearance: yellow solid; mp 72–74°C; $[\alpha]_{20}^{D}$ = +11.8 (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.69 (d, 3H, J = 7.3 Hz, CH₃), 2.77 (s, 3H, SCH₃), 3.76 (s, 3H, OCH₃), 4.81 (q, 1H, J = 7.3 Hz, CH), 6.97 (s, 1H, = C-H), 7.45-7.36 (m, 3H, Ar–H), 8.15 (d, 2H, J = 8.0 Hz, Ar–H); ¹³C NMR (75 MHz, CDCl₃): δ 13.56, 15.53, 49.51, 52.79, 124.31, 128.65, 129.89, 132.01, 134.40, 137.89, 163.91, 169.26, 169.66; IR (KBr) ν /cm⁻¹: 1265, 1404, 1438, 1645, 1729; MS: m/z = 305 (M⁺+1); calcd. for C₁₅H₁₆N₂O₃S (%): C, 59.19; H, 5.30; N, 9.20; found (%): C, 59.14; H, 5.31; N, 9.24.

(S)-2-[4-(4-Chlorobenzylidene)-2-methylthio-5-oxo-4,5-dihydro-imidazol -1-yl]propanoic acid methyl ester (4c). Appearance: yellow solid; p 104–106°C; $[α]_{20}^{D} = -32.0$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.68 (d, 3H, J =7.3Hz, CH₃), 2.78 (s, 3H, SCH₃), 3.80 (s, 3H, Ar–OCH₃), 4.81 (q, 1H, J = 7.3 Hz, CH), 6.89 (s, 1H, = C–H), 7.41 (d, 2H, J = 8.5 Hz, Ar–H), 8.09 (d, 2H, J = 8.5 Hz, Ar–H); ¹³C NMR (75 MHz, CDCl₃): δ 13.52, 15.52, 51.02, 52.89, 122.43, 128.80, 133.02, 135.50, 138.14, 164.69, 169.45, 169.92; IR (KBr) $ν/cm^{-1}$: 1243, 1491, 1637, 1722; MS: m/z = 339 (M⁺+1); calcd. for C₁₅H₁₅ClN₂O₃S (%): C, 53.17; H, 4.46; N, 8.27; found (%): C, 53.13; H, 4.41; N, 8.20.

(R)-2-[4-(4-Chlorobenzylidene)-2-methylthio-5-oxo-4,5-dihydro-imidazol -1-yl]propanoic acid methyl ester (4d). Appearance: yellow solid; mp 105–107°C; $[\alpha]_{20}^{D} = +31.1$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.67 (d, 3H, J =7.4 Hz, CH₃), 2.78 (s, 3H, SCH₃), 3.77 (s, 3H, Ar–OCH₃), 4.80 (q, 1H, J = 7.3 Hz, CH), 6.90 (s, 1H, = C–H), 7.39 (d, 2H, J = 8.5 Hz, Ar–H), 8.10 (d, 2H, J = 8.4 Hz, Ar–H); ¹³C NMR (75 MHz, CDCl₃): δ 13.57, 15.52, 49.97, 52.88, 122.75, 128.91, 133.02, 135.75, 138.13, 164.35, 169.15, 169.67; IR (KBr) ν/cm^{-1} : 1241, 1500, 1639, 1725; MS: $m/z = 339 (M^++1)$; calcd. for $C_{15}H_{15}ClN_2O_3S$ (%): C, 53.17; H, 4.46; N, 8.27; found (%): C, 53.21; H, 4.43; N, 8.32.

(S)-2-[4-(4-Methylbenzylidene)-2-methylthio-5-oxo-4,5-dihydro-imidazol -1-yl]propanoic acid methyl ester (4e). Appearance: yellow oil; $[α]_{20}^{D} = -39.9$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.68 (d, 3H, J = 7.2 Hz, CH₃), 2.40 (s, 3H, CH₃), 2.76 (s, 3H, SCH₃), 3.76 (s, 3H, OCH₃), 4.82 (q, 1H, J = 7.2 Hz, CH), 6.96 (s, 1H, = C-H), 7.25 (d, 2H, J = 7.8 Hz, Ar-H), 8.06 (d, 2H, J = 7.8 Hz, Ar-H); ¹³C NMR (75 MHz, CDCl₃): δ 13.46, 15.35, 21.58, 49.67, 52.78, 124.76, 129.54, 130.66, 131.76, 132.05, 140.57, 161.22, 169.19, 169.89; IR (LF) ν/cm⁻¹: 1254, 1497, 1595, 1710; MS: m/z = 319 (M⁺+1); calcd. for C₁₆H₁₈N₂O₃S (%): C, 60.36; H, 5.70; N, 8.80; found (%): C, 60.48; H, 5.74; N, 8.76.

(R)-2-[4-(4-Methylbenzylidene)-2-methylthio-5-oxo-4,5-dihydro-imidazol -1-yl]propanoic acid methyl ester (4f). Appearance: yellow oil; $[\alpha]_{20}^{D} = +41.1$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.65 (d, 3H, J = 7.2 Hz, CH₃), 2.40 (s, 3H, CH₃), 2.71 (s, 3H, SCH₃), 3.73 (s, 3H, OCH₃), 4.84 (q, 1H, J = 7.3 Hz, CH), 6.84 (s, 1H, = C-H), 7.27 (d, 2H, J = 7.8 Hz, Ar-H), 8.06 (d, 2H, J = 7.8 Hz, Ar-H); ¹³C NMR (75 MHz, CDCl₃): δ 13.51, 15.45, 21.73, 49.89, 52.82, 124.96, 129.61, 130.82, 131.81, 132.14, 140.59, 161.02, 169.29, 169.98; IR (LF) ν/cm^{-1} : 1253, 1490, 1589, 1715; MS: m/z = 319 (M⁺+1); calcd. for C₁₆H₁₈N₂O₃S (%): C, 60.36; H, 5.70; N, 8.80; found (%): C, 60.45; H, 5.76; N, 8.75.

(S)-2-[4-(4-Methoxybenzylidene)-2-methylthio-5-oxo-4,5-dihydro-imidaz ol-1-yl]propanoic acid methyl ester (4g). Appearance: yellow solid; mp 95–97°C; $[α]_{20}^{D} = -27.9$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 1.64 (d, 3H, J = 7.4 Hz, CH₃), 2.70 (s, 3H, SCH₃), 3.71 (s, 3H, OCH3), 3.80 (s, 3H, Ar–OCH₃), 4.77 (q, 1H, J = 7.4 Hz, CH), 6.92-6.89 (m, 3H, Ar–H & = C–H), 8.10 (d, 2H, J = 8.8 Hz, Ar–H); ¹³C NMR (75 MHz, CDCl₃): δ 13.46, 15.52, 49.80, 52.78, 55.29, 114.23, 124.62, 127.27, 133.83, 136.13, 161.13, 162.10, 169.32, 169.87; IR (KBr) ν/cm⁻¹: 1253, 1500, 1597, 1711; MS: m/z = 335 (M⁺+1); calcd. for C₁₆H₁₈N₂O₄S (%): C, 57.47; H, 5.43; N, 8.38; found (%): C, 57.37; H, 5.48; N, 8.35.

(R)-2-[4-(4-Methoxybenzylidene)-2-methylthio-5-oxo-4,5-dihydro-imidaz ol-1-yl]propanoic acid methyl ester (4h). Appearance: yellow solid; mp 97–99°C; $[\alpha]_{20}^{D} = +28.8 (c = 1; (CH_3)_2CO); {}^{1}H NMR (300 MHz, CDCl_3): \delta 1.64 (d, 3H, <math>J = 7.3$ Hz, CH₃), 2.72 (s, 3H, SCH₃), 3.75 (s, 3H, OCH₃), 3.82 (s, 3H, Ar–OCH₃), 4.78 (q, 1H, J = 7.3 Hz, CH), 6.93-6.90 (m, 3H, Ar–H & = C–H), 8.11 (d, 2H, J = 8.8 Hz, Ar–H); ${}^{13}C NMR (75 MHz, CDCl_3): \delta 13.45, 15.50, 49.73, 52.77, 55.27, 113.86, 114.19, 124.62,$ $127.21, 133.79, 136.07, 161.06, 162.10, 169.31, 169.83; IR (KBr) <math>\nu/cm^{-1}$: 1252, 1501, 1598, 1710; MS: m/z = 335 (M⁺+1); calcd. for C₁₆H₁₈N₂O₄S (%): C, 57.47; H, 5.43; N, 8.38; found (%): C, 57.40; H, 5.40; N, 8.42.

(S)-2-(4-Benzylidene-2-methylthio-5-oxo-4,5-dihydro-imidazol-1-yl)-3hydroxypropanoic acid methyl ester (4i). Appearance: yellow oil; $[\alpha]_{20}{}^{D} = -8.0$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 2.72 (s, 3H, SCH₃), 3.81 (s, 3H, OCH₃), 4.24-4.22 (m, 2H, CH₂), 4.64 (t, 1H, J = 5.0 Hz, CH), 6.98 (s, 1H, = C–H), 7.44-7.35 (m, 3H, Ar–H), 8.15 (d, 2H, J = 8.0 Hz, Ar–H); ¹³C NMR (75 MHz, CDCl₃): 13.59, 52.98, 58.11, 60.71, 125.49, 128.67, 130.18, 132.16, 134.17, 137.70, 164.03, 167.93, 170.47; IR (LF) ν /cm⁻¹: 1258, 1497, 1633, 1738; MS: m/z = 321 (M⁺+1); calcd. for C₁₅H₁₆N₂O₄S (%): C, 56.24; H, 5.03; N, 8.74; found (%): C, 56.30; H, 5.05; N, 8.70. (S)-3-Hydroxy-2-[4-(4-methoxybenzylidene)-2-methylthio-5-oxo-4,5-dih ydro-imidazol-1-yl]propanoic acid methyl ester (4j). Appearance: yellow oil; $[α]_{20}^{D} = -4.0$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 2.66 (s, 3H, SCH₃), 3.74 (s, 3H, OCH₃), 3.81 (s, 3H, Ar–OCH₃), 4.22-4.15 (m, 2H, CH₂), 4.63 (t, 1H, J =5.2 Hz, CH), 6.92-6.89 (m, 3H, Ar–H & = C–H), 8.08 (d, 2H, J = 8.7 Hz, Ar–H); ¹³C NMR (75 MHz, CDCl₃): δ 13.54, 52.89, 55.35, 58.11, 60.71, 114.28, 125.68, 127.12, 134.08, 135.99, 161.37, 162.36, 167.99, 170.48; IR (LF) ν/cm⁻¹: 1258, 1490, 1637, 1736; MS: m/z = 351 (M⁺+1); calcd. for C₁₆H₁₈N₂O₅S (%): C, 54.85; H, 5.18; N, 7.99; found (%): C, 54.92; H, 5.15; N, 7.92.

(S)-3-(1H-Indol-3-yl)-2-[4-(4-methoxybenzylidene)-2-methylthio-5-oxo-4,5-dihydro-imidazol-1-yl]propanoic acid methyl ester (4k). Appearance: yellow oil; $[\alpha]_{20}^{D} = -263.8$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 2.58 (s, 3H, SCH₃), 3.85-3.68 (m, 8H, CH₂ & Ar-OCH₃ & COOCH₃), 4.98-4.93 (m, 1H, CH), 8.10-6.89 (m, 11H, Ar-H & = C-H & N-H); ¹³C NMR (75 MHz, CDCl₃): δ 13.58, 25.02, 52.84, 55.33, 55.42, 111.17, 114.25, 118.38, 119.58, 122.11, 123.03, 124.51, 127.34, 133.81, 136.22, 161.11, 162.09, 168.70, 169.33; IR (LF) ν /cm⁻¹: 1255, 1439, 1499, 1597, 1704, 1742; MS: m/z = 450 (M⁺+1); calcd. for C₂₄H₂₃N₃O₄S (%): C, 64.13; H, 5.16; N, 9.35; found (%): C, 64.25; H, 5.14; N, 9.39.

(S)-2-[4-(4-Methoxybenzylidene)-2-methylthio-5-oxo-4,5-dihydro-imida zol-1-yl]succinic acid dimethyl ester (4l). Appearance: yellow solid; mp 137–138°C; $[α]_{20}^{D} = -103.9$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 2.77 (s, 3H, SCH₃), 3.42-3.35 (m, CH₂, 2H), 3.71 (s, 3H, COOCH₃), 3.78 (s, 3H, OCH₃), 3.87 (s, 3H, Ar–OCH₃), 5.14-5.09 (m, 1H, CH), 6.96-6.93 (m, 3H, Ar–H & = C–H), 8.12 (d, 2H, *J* = 8.8 Hz, Ar–H); ¹³C NMR (75 MHz, CDCl₃): δ 13.64, 34.17, 51.40, 52.24, 53.26, 55.42, 114.36, 125.07, 127.28, 133.98, 135.85, 161.31, 162.25, 168.92, 169.54, 171.51; IR (KBr) $ν/cm^{-1}$: 1244, 1434, 1502, 1596, 1735; MS: m/z = 393 (M⁺+1); calcd. for C₁₈H₂₀N₂O₆S (%): C, 55.09; H, 5.14; N, 7.14; found (%): C, 55.13; H, 5.10; N, 7.11.

(S)-2-[4-(4-Methoxybenzylidene)-2-methylthio-5-oxo-4,5-dihydro-imida zol-1-yl]pentanedioic acid dimethyl ester (4m). Appearance: yellow oil; $[\alpha]_{20}^{D} = -71.6$ (c = 1; (CH₃)₂CO); ¹H NMR (300 MHz, CDCl₃): δ 2.42-2.38 (m, 4H, 2CH₂) 2.75 (s, 3H, SCH₃), 3.67 (s, 3H, OCH₃), 3.76 (s, 3H, OCH₃), 3.86 (s, 3H, Ar-OCH₃), 4.80-4.75 (m, 1H, CH), 6.96-6.93 (m, 3H, Ar-H & = C-H), 8.13 (d, 2H, J = 8.7 Hz, Ar-H); ¹³C NMR (75 MHz, CDCl₃): δ 13.57, 24.41, 30.19, 51.76, 52.84, 53.67, 55.34, 114.29, 125.01, 127.25, 133.90, 135.93, 161.25, 162.31, 169.01, 169.63, 172.63; IR (LF) ν/cm^{-1} : 1257, 1440, 1501, 1599, 1739; MS: m/z = 407 (M⁺+1); calcd. for C₁₉H₂₂N₂O₆S (%): C, 56.15; H, 5.46; N, 6.89; found (%): C, 56.10; H, 5.43; N, 6.84.

REFERENCES

- (a) N. B. Mehta, C. A. R. Diuguid, and F. E. Soroko, J. Med. Chem., 24, 465 (1981); (b) C. H. Kwon, M. T. Iqbal, and J. N. D. Wurpel, J. Med. Chem., 34, 1845 (1991); (c) H. Joshi, P. Upadhyay, D. Karia, and A. J. Baxi, Eur. J. Med. Chem., 38, 837 (2003).
- 2. A. A. El-Barbary, A. I. Khodair, E. B. Pedersen, and C. Nielsen, J. Med. Chem., 37, 73 (1994).
- 3. A. I. Khodair and P. Bertrand, Tetrahedron, 54, 4859 (1998).
- 4. H. Sato, M. Tsuda, K. Watanabe, and J. Kobayashi, Tetrahedron, 54, 8687 (1998).
- 5. B. M. Nilsson, H. M. Vargas, and U. Hacksell, J. Med. Chem., 35, 3270 (1992).
- 6. D. L. Shaner, P. C. Anderson, and M. A. Stidham, Plant Physiol., 76, 545 (1984).

- G. Lacroix, R. Peignier, R. Pepin, J. P. Bascou, J. Perez, and C. Schmitz, US 6002016 (1999); Chem. Abstr., 132, 35698e (2000).
- 8. T. E. Chin, R. B. Wong, J. L. Pont, and A. E. Karu, J. Agric. Food. Chem., 50, 3380 (2002).
- 9. A. Williams, Pestic. Sci., 46, 3 (1996).
- (a) P. M. Fresneda and P. Molina, *Synlett*, 1 (2004); (b) P. Molina and M. J. Vilaplana, *Synthesis*, 1197 (1994); (c) M. W. Ding, B. Q. Fu, and L. Cheng, *Synthesis*, 1067 (2004); (d) M. W. Ding, S. J. Yang, and J. Zhu, *Synthesis*, 75 (2004); (e) M. W. Ding, S. Z. Xu, and J. F. Zhao, *J. Org. Chem.*, **69**, 8366 (2004).
- (a) M. W. Ding, Y. Sun, and Z. J. Liu, *Synth. Commun.*, **33**, 1267 (2003); (b) F. L. Yang, Z. J. Liu, X. B. Huang, and M. W. Ding, *J. Heterocycl. Chem.*, **41**, 77 (2004); (c) X. B. Huang, Z. J. Liu, F. L. Yang, and M. W. Ding, *Phosphorus, Sulfur, and Silicon*, **182**, 939 (2007).
- 12. P. Molina, A. Pastor, and M. J. Vilaplana, Tetrahedron, 49, 7769 (1993).
- (a) W. Marckwald, M. Neumark, and R. Stelzner, *Berichte*, 24, 3278 (1891); (b) R. Jakše, S. Rečnik, J. Svete, A. Golobič, L. Golič, and B. Stanovnik, *Tetrahedron*, 57, 8395 (2001); (c) J. R. Chérouvrier, F. Carreaux, and J. P. Bazureau, *Tetrahedron Lett.*, 43, 3581 (2002); (d) J. R. Chérouvrier, F. Carreaux, and J. P. Bazureau, *Tetrahedron Lett.*, 43, 8745 (2002).
- 14. G. M. Sheldrick, SHELXS-97, University of Göttingen, Germany (1997).
- 15. G. M. Sheldrick, SHELXL-97, University of Göttingen, Germany (1997).
- 16. Crystallographic data for the structure 3c and 3d in this article have been deposited with the Cambridge Crystallographic Data Center as supplementary publication number CCDC 704007 and 704008, respectively. Copies of the data can be obtained free of change on application to CCDC, 12 Union Road, Cambridge CB21EZ, U. K.; e-mail: deposit@ccdc.cam.ac.uk.
- HPLC-separation conditions of 3c: Chiralcel OD-H, 22°C, 254 nm, 80:20 hexane:*i*-PrOH, 0.8 mL/min; t_R = 18.6 min (S); HPLC-separation conditions of 3d: Chiralcel OD-H, 22°C, 254 nm, 80:20 hexane:*i*-PrOH, 0.8 mL/min; t_R = 13.3 min (R).
- 18. HPLC-separation conditions of **4c**: Chiralcel OD–H, 22°C, 254 nm, 80:20 hexane:*i*-PrOH, 0.8 mL/min; $t_R = 9.7 \min(R)$, $t_R = 11.3 \min(S)$; HPLC-separation conditions of **4d**: Chiralcel OD–H, 22°C, 254 nm, 80:20 hexane:*i*-PrOH, 0.8 mL/min; $t_R = 9.6 \min(R)$, $t_R = 10.9 \min(S)$.